Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
54.60    -1.40 (-2.50%)
Bid:
52.60
Ask:
56.60
Spread: 4.00 (7.605%)
Market Cap: £45.60m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Offer Update

3 Jun 2008 07:00

RNS Number : 7987V
Mentor Graphics Corporation
03 June 2008
 



Not for release, publication or distribution, in whole or in part, in or into or from the United StatesCanada or Australia or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction

CASH OFFER

for

FLOMERICS GROUP PLC

by

MENTOR GRAPHICS CORPORATION

Offer Update

In his letter to Flomerics Shareholders dated 30 May 2008, the Chairman and Chief Executive Officer of Mentor stated: "In the letter and accompanying document sent to you by your Chairman on 27 May 2008, Flomerics portrayed a superficially attractive picture, both regarding the current trading of Flomerics and its valuation. However, I wish to remind you that as well as acquiring a substantial number of shares from institutional investors at 104 pence per share, Mentor also acquired 20.1 per cent. of Flomerics share capital from Pricap, a sophisticated financial institution active in this market. Pricap also had a representative on the Board of Flomerics and, therefore, was in a position to make an informed decision as to the fair value of a Flomerics Share. I continue to believe that our cash offer is an attractive one to all shareholders."

Mentor has been asked by the Panel Executive to clarify that the decision by Pricap to sell its Flomerics Shares to Mentor, which was announced on 14 March 2008, was taken solely on the basis of publicly available information and was taken without any input from and without the knowledge of Wolfgang Biedermann, the individual that Mentor considered to be a representative of Pricap on the Flomerics Board.

Enquiries:

Mentor

Dennis Weldon

Ryerson Schwark Tel: +1 503 685 7000

Cenkos Securities plc 

Nicholas Wells  Tel: +44 20 7397 8900

Bell Pottinger Corporate & Financial

David Rydell

Olly Scott Tel: +44 20 7861 3232

 

Definitions used in the Offer Document dated 17 May 2008 have the same meaning when used in this announcement, unless the context requires otherwise. 

This press announcement does not constitute an offer or invitation to purchase any securities or a solicitation of an offer to purchase any securities, pursuant to the Offer or otherwise. The Offer is being made solely by means of the Offer Document and, in the case of Flomerics Shares held in certificated form, the accompanying Form of Acceptance which contains the full terms and conditions of the Offer, including details of how the Offer may be accepted. 

 

Dealing disclosure requirements

Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the 'City Code'), if any person is, or becomes, 'interested' (directly or indirectly) in one per cent. or more of any class of 'relevant securities' of Flomerics, all 'dealings' in any 'relevant securities' of Flomerics (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by no later than 3.30 pm (London time) on the London Business Day following the date of the relevant transaction. This requirement will continue until the date on which the Offer becomes, or is declared, unconditional as to acceptance, lapses or is otherwise withdrawn or on which the 'offer period' otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an 'interest' in 'relevant securities' of Flomerics they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the City Code, all 'dealings' in 'relevant securities' of Flomerics by Mentor or Flomerics or by any of their respective 'associates', must be disclosed by no later than 12.00 noon (London time) on the London Business Day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.

'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a 'dealing' under Rule 8, you should consult the Panel.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPFKBKPCBKDBAK
Date   Source Headline
17th May 20242:54 pmRNSNotice of AGM
9th May 20247:00 amRNSAnnual Financial Report
1st May 20247:00 amRNSHolding(s) in Company
18th Apr 20244:10 pmRNSDirector/PDMR Shareholding
27th Mar 20242:28 pmRNSClarification note regarding Dividend - REPLACE
26th Mar 20247:16 amRNS2023 Annual Unaudited Results
25th Mar 202411:44 amRNSNotice of Results
1st Feb 202410:38 amRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSTrading update
19th Dec 20237:00 amRNSHolding(s) in Company
25th Oct 202311:42 amRNSHolding(s) in Company
31st Aug 20234:25 pmRNSBoard Update
31st Aug 20237:00 amRNSPDMRs - Director Dealings
30th Aug 20237:00 amRNS2023 Half-year report
31st Jul 20237:00 amRNSTrading update & Notice of Half-year results
13th Jun 20231:42 pmRNSResult of AGM
5th Jun 20237:00 amRNSAwards under Long-Term Incentive Plan
5th Jun 20237:00 amRNSBoard update
19th May 20237:00 amRNSAvailability of Documents & Notice of 2023 AGM
15th May 20237:00 amRNSDirector Dealing
26th Apr 20237:01 amRNSAudited Annual Financial Report FY2022
12th Apr 20237:00 amRNSDirectorate Change
12th Apr 20237:00 amRNSUnaudited Preliminary Results-year ended 31.12.22
24th Mar 20237:00 amRNSNotice of Results - revised date
9th Mar 20238:00 amRNSAnnual Results and Presentation via IMC Platform
26th Jan 20237:00 amRNSTrading Update and Notice of Results
11th Jan 20237:00 amRNSBoard changes: NED Appointment & NED Retirement
21st Dec 20224:39 pmRNSHolding(s) in Company
31st Aug 20227:00 amRNSHalf-year Report - six months ended 30 June 2022
8th Aug 20226:27 pmRNSHolding(s) in Company
4th Aug 20227:30 amRNS2022 Half-Year Results - Investor Presentation
1st Aug 20227:00 amRNSGroup Trading Update & Notice of HY1 2022 results
21st Jul 20221:03 pmRNSHolding(s) in Company
1st Jun 20222:23 pmRNSResult of AGM and Total Voting Rights
18th May 20227:00 amRNSDirector/PDMR Shareholding
5th May 20222:20 pmRNS2021 Annual Report & Notice of 2022 AGM
3rd May 20227:00 amRNSGrant of Options under Long-Term Incentive Plan
30th Mar 20221:21 pmRNSDirector/PDMR Shareholding
29th Mar 20227:00 amRNSFY2021 Results & publication of the Annual Report
25th Mar 20225:36 pmRNSHolding(s) in Company
7th Mar 20229:00 amRNSNotice of Results and Investor Presentation
21st Feb 20225:49 pmRNSHolding(s) in Company
26th Jan 20227:01 amRNSTrading Statement
26th Jan 20227:00 amRNSAppointment of Nominated Adviser and Sole Broker
20th Jan 20224:41 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
20th Dec 202112:58 pmRNSHolding(s) in Company
10th Dec 20214:41 pmRNSSecond Price Monitoring Extn
10th Dec 20214:36 pmRNSPrice Monitoring Extension
15th Nov 20217:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.